Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...
While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.
Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...
While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...
Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...
Don't want to spend a fortune and break the bank on investing in growth stocks? The ones listed here all cost less than $100.
Eli Lilly er danske Novo Nordisks største konkurrent på medicinalmarkedet inden for diabetes og overvægt. Novo offentliggjorde sit årsregnskab onsdag morgen. Det viste et overskud på 101 milliard ...
Chief executive Emma Walmsley said ministers must work with the sector to boost investment amid growing concerns about doing ...
Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline. Click for my LLY stock update.
Der er parkeringsplads lige bag biografen (Smedegades P-plads). Lørdag og søndag er der parkering uden tidsbegrænsning. Alle andre dage kan man holde der tre timer i tidsrummet 8-18. Kommer man efter ...